---
schema_version: "secwatch.filing_event.v1"
accession: "0000078890-26-000063"
form_type: "8-K"
ticker: "BCO"
cik: "0000078890"
company_name: "BRINKS CO"
filed_at: "2026-10-08T10:00:54+00:00"
generated_at: "2026-10-12T15:41:30.618462+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Brink's receives CMA acceptance in principle of remedy for NCR Atleos acquisition

## Summary
- UK CMA accepted in principle Brink's proposed remedy to divest NoteMachine/TestLink UK, avoiding a CMA Phase 2 referral for the NCR Atleos acquisition.
- Brink's said the NCR Atleos acquisition remains on track to close early in Q1 2027, with sale process for NoteMachine/TestLink UK progressing and prospective buyers engaged.
- CEO Mark Eubanks said the remedy does not impact the $200 million in annual run-rate cost synergies expected within three years of closing the transaction.
- Brink's and NCR Atleos trade on NYSE under BCO and NATL, respectively.

## SEC filing metadata
- accession: 0000078890-26-000063
- form_type: 8-K
- ticker: BCO
- cik: 0000078890
- company_name: BRINKS CO
- filed_at: 2026-10-08T10:00:54+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78890/000007889026000063/0000078890-26-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78890/000007889026000063/bco-20261008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078890-26-000063
- JSON: https://secwatch.observer/filing/0000078890-26-000063.json
- Plain text: https://secwatch.observer/filing/0000078890-26-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.